Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis announced key financial metrics as of April 30, 2021, revealing a total of 45,461,310 shares in capital and 51,526,159 voting rights. The company focuses on developing allogeneic CAR-T immunotherapies for cancer treatment, utilizing its proprietary gene editing technology, TALEN®. Cellectis aims to address unmet medical needs in cancers like acute myeloid leukemia and multiple myeloma, backed by over 21 years of expertise. The company is listed on the Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).

Positive

• Developing allogeneic CAR-T immunotherapies aimed at cancer treatment.
• Utilizes proprietary TALEN® gene editing technology.
• Over 21 years of expertise in gene editing.
• Focus on unmet medical needs for multiple cancers.

Negative

• None.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
04/30/2021	45,461,310	51,526,159

About Cellectis
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN^®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).

Cellectis headquarters are in Paris, France, with additional locations in New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com.

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

TALEN^® is a registered trademark owned by Cellectis.

For further information, please contact:

Media contacts:
Pascalyne Wilson, Communications Manager, +33776991433, media@cellectis.com

IR contact:
Simon Harnest, SVP, Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com

Attachment

• Voting_Rights_PR_April_EN_docx

FAQ

What are the latest share metrics for Cellectis as of April 30, 2021?

As of April 30, 2021, Cellectis reported a total of 45,461,310 shares in capital and 51,526,159 voting rights.

What is Cellectis focused on in the biopharmaceutical industry?

Cellectis is focused on developing allogeneic CAR-T immunotherapies to treat various cancers, including AML and multiple myeloma.

What technology does Cellectis use for gene editing?

Cellectis utilizes its proprietary TALEN® gene editing technology in its development of cancer therapies.

On which stock exchanges is Cellectis listed?

Cellectis is listed on the Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).